Drug Profile
Research programme: receptor protein tyrosine kinase modulators - 3B Pharmaceuticals
Latest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator 3B Pharmaceuticals
- Class Imaging agents; Peptide diagnostics; Radiopharmaceutical diagnostics
- Mechanism of Action Receptor protein-tyrosine kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Cancer in Germany
- 28 Feb 2018 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in Germany
- 13 Jan 2014 Preclinical trials in Cancer (diagnosis) in Germany (unspecified route)